Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-0.10 Insider Own0.10% Shs Outstand2.26B Perf Week-1.81%
Market Cap133.71B Forward P/E8.12 EPS next Y7.40 Insider Trans-8.46% Shs Float2.25B Perf Month3.23%
Income-563.00M PEG- EPS next Q1.49 Inst Own76.20% Short Float0.52% Perf Quarter3.58%
Sales34.86B P/S3.84 EPS this Y-33.90% Inst Trans0.17% Short Ratio1.16 Perf Half Y-3.88%
Book/sh21.69 P/B2.77 EPS next Y18.05% ROA-0.50% Target Price73.69 Perf Year10.59%
Cash/sh9.74 P/C6.17 EPS next 5Y22.15% ROE-1.30% 52W Range45.76 - 68.34 Perf YTD-6.32%
Dividend1.80 P/FCF15.51 EPS past 5Y10.90% ROI5.50% 52W High-12.01% Beta0.64
Dividend %2.99% Quick Ratio1.40 Sales past 5Y10.50% Gross Margin69.90% 52W Low31.40% ATR1.21
Employees30000 Current Ratio1.50 Sales Q/Q61.50% Oper. Margin15.00% RSI (14)47.43 Volatility1.88% 2.07%
OptionableYes Debt/Eq0.95 EPS Q/Q-104.30% Profit Margin-1.60% Rel Volume0.73 Prev Close60.76
ShortableYes LT Debt/Eq0.85 EarningsNov 05 BMO Payout- Avg Volume10.01M Price60.13
Recom1.90 SMA20-0.33% SMA50-0.78% SMA200-0.28% Volume7,323,713 Change-1.04%
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
May-03-19Resumed JP Morgan Overweight $62
Jan-15-19Upgrade Societe Generale Sell → Buy
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-23-20 10:05AM  
07:45AM  
07:11AM  
Oct-22-20 10:15AM  
Oct-21-20 10:48AM  
Oct-19-20 05:25PM  
05:21PM  
04:27PM  
03:24PM  
12:06PM  
11:55AM  
11:47AM  
09:50AM  
06:59AM  
06:06AM  
Oct-18-20 09:30AM  
Oct-17-20 07:11AM  
Oct-16-20 03:24PM  
07:45AM  
07:12AM  
Oct-10-20 06:06PM  
Oct-09-20 07:46PM  
09:23AM  
Oct-08-20 04:13PM  
04:11PM  
11:39AM  
Oct-07-20 04:22PM  
09:33AM  
07:43AM  
07:30AM  
07:19AM  
07:17AM  
06:59AM  
Oct-06-20 03:52PM  
12:10PM  
08:00AM  
Oct-05-20 04:26PM  
02:47PM  
02:35PM  
01:26PM  
12:38PM  
11:41AM  
11:27AM  
11:13AM  
10:45AM  
10:24AM  
09:15AM  
09:11AM  
08:25AM  
08:19AM  
06:49AM  
06:40AM  
06:30AM  
06:29AM  
Oct-03-20 06:36AM  
Oct-02-20 04:17PM  
04:12PM  
02:07PM  
06:59AM  
06:59AM  
Oct-01-20 01:55PM  
Sep-29-20 06:59AM  
Sep-26-20 08:00AM  
Sep-25-20 09:27AM  
05:16AM  
Sep-24-20 04:15PM  
Sep-23-20 01:28PM  
Sep-22-20 04:22PM  
01:20PM  
06:59AM  
Sep-21-20 04:16PM  
12:31PM  
12:30PM  
Sep-20-20 08:09AM  
Sep-19-20 12:30PM  
Sep-18-20 06:05PM  
10:53AM  
07:17AM  
Sep-17-20 04:16PM  
03:50PM  
11:28AM  
06:59AM  
06:15AM  
Sep-15-20 12:27PM  
12:09PM  
07:30AM  
06:59AM  
Sep-14-20 09:48AM  
Sep-12-20 08:30AM  
Sep-11-20 02:39PM  
10:20AM  
Sep-10-20 06:22PM  
04:47PM  
04:15PM  
06:59AM  
Sep-09-20 08:00PM  
08:00PM  
05:21AM  
Sep-08-20 07:23PM  
04:15PM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in the following therapeutic classes: hematology, oncology, cardiovascular, and immunology. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, and Ubiquigent Limited; clinical collaboration agreement with NeoImmuneTech, Inc.; and partnership with Astrazeneca Plc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Santiago Karen MurphySVP & ControllerSep 01Option Exercise0.0064208,390Sep 02 04:33 PM
Caforio GiovanniChairman and CEOAug 31Sale62.7039,8402,497,968445,584Sep 02 04:34 PM
Eid JosephSVP,Head Glob. Medical AffairsAug 17Sale64.005,327340,9282,534Aug 19 06:15 PM
LEUNG SANDRAEVP, General CounselAug 13Sale63.24141,4208,943,401432,744Aug 17 04:55 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,402080,698Aug 04 04:43 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,35609,356Jul 02 04:56 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,06908,115Jul 02 04:54 PM
Paliwal Dinesh CDirectorJun 15Buy54.509,174499,98322,109Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 14Option Exercise0.0055808,650Jun 16 05:16 PM
Haller Julia ADirectorJun 14Option Exercise0.0055806,819Jun 16 05:15 PM
Haller Julia ADirectorJun 13Option Exercise0.0090306,261Jun 16 05:15 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.0090308,092Jun 16 05:16 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,15408,599Jun 09 07:15 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94905,358Jun 05 04:39 PM
BONNEY MICHAEL WDirectorJun 03Option Exercise0.002,94907,189Jun 05 04:40 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 22Sale61.013,200195,23216,086May 26 05:17 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 19Sale62.6825,0001,567,00026,777May 21 05:22 PM
VESSEY RUPERTEVP, Research & Early Dev.May 01Option Exercise0.0010,707059,050May 05 04:49 PM
AHMED NADIMEVP and President, HematologyMay 01Option Exercise0.002,908027,463May 05 04:49 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0030,519058,379Mar 12 06:18 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,8060152,400Mar 12 06:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0031,169058,421Mar 12 06:17 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.005,06307,778Mar 12 06:17 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0051,5980588,175Mar 12 06:15 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.001,57106,652Mar 12 06:13 PM
Elicker John EEVP, Investor RelationsMar 10Option Exercise0.0018,407075,102Mar 12 06:14 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00211,7960544,032Mar 12 06:11 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,007020,091Mar 12 06:12 PM
Bancroft Charles AEVP, Head of IntegrationMar 10Option Exercise0.0071,8680153,637Mar 12 06:11 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0021,426026,091Mar 12 06:11 PM
Elicker John EEVP, Investor RelationsMar 04Sale61.0115,805964,26358,666Mar 06 05:20 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Option Exercise51.6993,4684,831,452132,651Mar 04 06:19 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 02Sale60.5984,3085,108,22248,343Mar 04 06:19 PM
AHMED NADIMPresident, HematologyMar 01Option Exercise0.0017,204033,028Mar 03 08:04 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579044,766Mar 03 08:04 PM
VESSEY RUPERTPres., Research & Early Dev.Mar 01Option Exercise0.0023,349048,106Mar 03 08:05 PM
AHMED NADIMPresident, HematologyFeb 04Option Exercise0.002,076016,895Feb 06 08:48 PM
VESSEY RUPERTPres., Research & Early Dev.Feb 04Option Exercise0.003,592025,920Feb 06 08:49 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0012,373026,281Jan 03 07:00 PM
VESSEY RUPERTPres., Research & Early Dev.Dec 31Option Exercise0.0016,060030,778Jan 03 07:00 PM
Dubow AdamChief Compliance & Ethics OffiDec 05Sale58.811,740102,32915,749Dec 09 04:44 PM
BONNEY MICHAEL WDirectorDec 04Buy58.90885,1837,189Jun 09 07:16 PM
Eid JosephSVPHead Global Medical AffairsDec 01Option Exercise0.002,82504,995Dec 03 05:28 PM
Schmukler Louis SPres., Global Mfg. & SupplyNov 05Sale56.5625,0001,414,00031,963Nov 06 04:54 PM
Elicker John ESVP, Public Affairs & IRNov 05Sale56.6615,000849,90074,471Nov 06 04:54 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.